Cardiome is pleased to have received this approval in South Africa and is dedicated to partnering BRINAVESS in this important pharmaceutical market as it continues focusing direct sales efforts on key countries in Europe.
One of the largest countries in Africa in terms of established pharmaceutical markets, South Africa saw total pharmaceutical sales reaching $3.7 billion USD in 2011, according to research conducted by IMS Health.
A biopharmaceutical company, Cardiome is engaged in the discovery, development, and commercialization of new therapies to improve the health of patients across the globe. BRINAVESS is currently the company’s only marketed product and has been approved in Europe and other territories.
For more information about Cardiome, visit www.cardiome.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html
